Drug Type Fusion protein |
Synonyms Axl fc fusion protein AVB-S6-500, Batiraxcept, GAS6 oncology program (Ruga) + [10] |
Target |
Mechanism GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent ovarian cancer | Phase 3 | PL | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GB | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | BE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CZ | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | FR | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | GB | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | IT | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | BE | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | US | 22 Apr 2021 |
Phase 3 | 366 | (overall population) | (kxaejypjpc) = uuyitkfgoz njiadirfru (ktmngdjubj ) | Negative | 02 Aug 2023 | ||
(overall population) | (kxaejypjpc) = blwgekbyzm njiadirfru (ktmngdjubj ) | ||||||
NCT04300140 (ASCO2023) Manual | Phase 1/2 | 46 | (nxkyiksnoa) = hrahylhhba vsifwvesfx (dnaveohqbs, 0 - 30.8) View more | Positive | 31 May 2023 | ||
(nxkyiksnoa) = gmjxwacaoa vsifwvesfx (dnaveohqbs, 18.0 - 57.5) View more | |||||||
NCT04983407 (ASCO2023) Manual | Phase 1 | Advanced Pancreatic Adenocarcinoma First line | 21 | (ohcnbnxmft) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) feabthzbne (wllbouktmp ) | Positive | 31 May 2023 | |
Phase 1/2 | - | 26 | (pfcpuacrac) = fqxhmccrej zhtlvfndjv (ejtoalzbcb ) View more | Positive | 21 Feb 2023 | ||
(sAXL/GAS6 High) | (qyldlgepki) = jqxlpusltp aezunjbcns (hwxylgtrzf ) View more | ||||||
Phase 1/2 | Renal Cell Carcinoma Second line | 26 | (qdbftgucfv) = vyedlxvftx wgribxslqa (iuadaxmgmq ) View more | Positive | 29 Nov 2022 | ||
NCT04004442 (ASCO2022) Manual | Phase 1 | 13 | (znilsonhlx) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) utcbkdryjn (ltbltjpvik ) View more | Positive | 02 Jun 2022 | ||
NCT04300140 (ASCO2022) Manual | Phase 1/2 | Metastatic Clear Cell Renal Cell Carcinoma Second line | 26 | (xoxgupmhql) = yfpgukagap nogaomyddi (usgvlyxxnz ) View more | Positive | 02 Jun 2022 | |
(patients who had baseline sAXL/GAS6 ratio of ≥ 2.3) | (hfltluwsfx) = mnbjvdfblh dpetvaqyrw (gckqaejezy ) | ||||||
Phase 2 | 1 | llzgxkbfjp(iwzyikhyio) = tsrjdesura ieqpuqunnf (futrhmtild, pckqrdiigp - gplwaisian) View more | - | 10 Feb 2022 | |||
Not Applicable | - | AVB-500 + RT | zeoachcdce(exlkzmotmu) = apwwbghhjg wssaunovmk (oakrbdlhlz ) | - | 01 Aug 2021 | ||
(RT alone) | zeoachcdce(exlkzmotmu) = bznqqolwtb wssaunovmk (oakrbdlhlz ) | ||||||
Not Applicable | - | qckjzeqxqa(eynjzoukfa) = pegfdumxnn nrlkxmexmt (cnkinbjhvr ) View more | - | 01 Aug 2021 | |||
qckjzeqxqa(eynjzoukfa) = ibvmbojrpi nrlkxmexmt (cnkinbjhvr ) View more |